Suspended
DHEADoes Dehydroepiandrosterone (DHEA) Improve IVF Outcomes in Poor Responders? A Randomised, Double-blind, Placebo Controlled Trial
What is being tested
Dehydroepiandrosterone
+ Placebo
Drug
Who is being recruted
Urogenital Diseases+4
+ Genital Diseases
+ Female Urogenital Diseases and Pregnancy Complications
From 40 to 42 Years
+6 Eligibility Criteria
How is the trial designed
Treatment Study
Placebo-ControlledPhase 2 & 3
Interventional
Study Start: October 2017
Summary
Principal SponsorHomerton University Hospital NHS Foundation Trust
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: October 8, 2017
Actual date on which the first participant was enrolled.Poor responders to ovarian stimulation for IVF may be either predicted or evidenced from previous treatment. The ESHRE criteria for poor responders will be used to select candidates for this trial. A power calculation determined that 200 subjects should be recruited to each arm to receive either DHEA or placebo.
Official TitleDoes Dehydroepiandrosterone (DHEA) Improve IVF Outcomes in Poor Responders? A Randomised, Double-blind, Placebo Controlled Trial
Principal SponsorHomerton University Hospital NHS Foundation Trust
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
400 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Female
Biological sex of participants that are eligible to enroll.From 40 to 42 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Urogenital DiseasesGenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsGenital Diseases, FemaleInfertilityInfertility, FemaleFemale Urogenital Diseases
Criteria
3 inclusion criteria required to participate
Age ≥ 40 years
Markers for poor ovarian reserve (AMH <7 pmol/L(<1.1 ng/ml) and/or AFC< 7)
Previous poor response to ovarian stimulation ( ≤3 oocytes with a conventional stimulation protocol)
3 exclusion criteria prevent from participating
Women > 42 years
Women with premature ovarian failure / premature menopause (FSH>40 U/L). Women already taking DHEA.
Patients with a known allergy to the trial drug or any of the active ingredients in the placebo.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
Experimental75mg Dehydroepiandrosterone once daily for minimum ten weeks prior to starting ovarian stimulation
Group II
Placebo75mg placebo once daily for minimum ten weeks prior to starting ovarian stimulation
Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
SuspendedOne Study Center